Home › Trials › NCT06615921

Evaluating Maribavir for Cytomegalovirus Infection in Adults After Transplant

A Multi-country, Multi-center, Retrospective Chart Review to Describe the Use of Maribavir and Its Effectiveness in Patients With Post-Transplant Cytomegalovirus Infection/Disease

Observational Takeda · NCT06615921

This study is testing if Maribavir can help adults who have had a transplant get rid of Cytomegalovirus from their blood.

Quick facts

Study typeObservational
Enrollment150 (estimated)
Ages18 Years and up
SexAll
SponsorTakeda Industry-sponsored
Locations45 sites (Vienna and 44 other locations)
Trial IDNCT06615921 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the effectiveness of Maribavir in eliminating Cytomegalovirus (CMV) from the bloodstream of adults who have undergone a transplant. It involves retrospective data collection from medical records, focusing on two periods: before and after the initiation of Maribavir treatment. The study will analyze patient profiles, treatment history, and healthcare resources utilized for managing CMV infections. The data collected will help understand the real-world application of Maribavir in clinical settings.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older who have received a hematopoietic stem cell transplant or solid organ transplant and have been diagnosed with CMV infection.

Not a fit: Patients who have not consented to participate or those involved in other clinical trials investigating Maribavir may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide insights into effective management strategies for CMV infections in post-transplant patients.

How similar studies have performed: Previous studies have shown promise in using Maribavir for CMV treatment, indicating potential for success in this observational approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion criteria:

* Aged greater than or equal to (\>=) 18 years at the time of consent or start of chart abstraction in case a consent waiver will be allowed as per local regulation.
* Received an HSCT/SOT.
* Diagnosed with CMV infection/disease any time after the HSCT/SOT date.
* Initiated maribavir at least 4 months before the chart abstraction date (or at time of Central Ethics Committee \[CEC\]/Local Ethics Committee \[LEC\] submission as per local regulation).
* Participants with hospital medical chart available, who signed an informed consent form before starting any study procedures (unless waiver is allowed as per local regulation).

Exclusion criteria:

* Participants who do not provide informed consent, where consent is required per country regulations.
* Participants who participated to Clinical Trials investigating maribavir.

Where this trial is running

Vienna and 44 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions CytomegalovirusDrug Therapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.